Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers
Latest Information Update: 20 Jun 2024
Price :
$35 *
At a glance
- Drugs Respiratory syncytial virus vaccine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms VAD00001
- Sponsors Sanofi; Sanofi Pasteur
- 16 May 2023 Status changed from active, no longer recruiting to completed.
- 29 Mar 2023 Planned End Date changed from 14 Apr 2023 to 13 Apr 2023.
- 29 Mar 2023 Planned primary completion date changed from 14 Apr 2023 to 13 Apr 2023.